1. Home
  2. TGE vs IFRX Comparison

TGE vs IFRX Comparison

Compare TGE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TGE

The Generation Essentials Group Class A Ordinary Shares

N/A

Current Price

$1.65

Market Cap

66.4M

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$1.03

Market Cap

67.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TGE
IFRX
Founded
2023
2007
Country
France
Germany
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.4M
67.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TGE
IFRX
Price
$1.65
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
125.1K
635.9K
Earning Date
10-20-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
$130,212,000.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
$3.36
N/A
Revenue Growth
316.50
N/A
52 Week Low
$0.78
$0.71
52 Week High
$37.02
$2.77

Technical Indicators

Market Signals
Indicator
TGE
IFRX
Relative Strength Index (RSI) N/A 47.91
Support Level N/A $0.93
Resistance Level N/A $1.10
Average True Range (ATR) 0.00 0.08
MACD 0.00 -0.00
Stochastic Oscillator 0.00 39.40

Price Performance

Historical Comparison
TGE
IFRX

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: